Key result
Geniposide reduces TAC-induced cardiac hypertrophy and fibrosis by suppressing the TGF-β1/Smad2 pathway.
Why the study?
Cardiac fibrosis contributes to heart failure pathogenesis, and geniposide improves skeletal muscle fibrosis, prompting investigation into its cardioprotective effects and mechanisms in cardiac fibrosis.
Does geniposide alleviate pressure overload-induced cardiac fibrosis and hypertrophy in preclinical models?
Does geniposide alleviate pressure overload-induced cardiac fibrosis and hypertrophy in preclinical models?
Geniposide demonstrates cardioprotective effects against pressure overload-induced cardiac fibrosis and hypertrophy via suppression of the TGF-β1/Smad2 pathway in preclinical models.
Answers are grounded in this paper and cite their sources.
Supports geniposide testing in pressure-overload models; leaves open human translation for hypertrophy and fibrosis.
BACKGROUND: Cardiac fibrosis is one of the main contributors to the pathogenesis of heart failure. Geniposide (GE), a major iridoid in gardenia fruit extract, has recently been reported to improve skeletal muscle fibrosis through the modulation of inflammation response. This investigation aimed to illuminate the cardio-protective effect and the potential mechanism of GE in cardiac fibrosis. MATERIAL AND METHODS: A transverse aortic contraction (TAC) induction mice model was established and GE (0 mg/kg; 10 mg/kg; 20 mg/kg; 40 mg/kg) was administered by oral gavage daily for 4 weeks. Hemodynamic parameters, Masson's trichrome stain, and hematoxylin-eosin (HE) staining were estimated and cardiomyocyte fibrosis, interstitial collagen levels, and hypertrophic markers were analyzed using qPCR and western blot. In vitro, H9C2 cells were exposed to the Ang II (1 μM) pretreated with GE (0.1 μM, 1 μM, and 10 μM). Cardiomyocyte apoptosis was detected. Moreover, the transforming growth factor β1 (TGF-β1)/Smad2 pathway was assessed in vivo and in vitro. RESULTS: GE significantly ameliorated TAC-induced cardiac hypertrophy, ventricular remodeling, myocardial fibrosis, and improved cardiac function in vivo, and it inhibited Ang II-induced cardiomyocyte apoptosis in vitro. We further observed that the inflammatory channel TGF-β1/Smad2 pathway was suppressed by GE both in vivo and in vitro. CONCLUSION: These results indicate that GE inhibited myocardial fibrosis and improved hypertrophic cardiomyocytes with attenuated the TGF-β1/Smad2 pathway and proposed to be an important therapeutic of cardiac fibrosis reduced by TAC.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2023) studied Cardiac fibrosis. Geniposide (GE) vs. 0 mg/kg was evaluated on Cardiac hypertrophy, ventricular remodeling, myocardial fibrosis, and cardiac function. Geniposide significantly ameliorated TAC-induced cardiac hypertrophy, ventricular remodeling, and myocardial fibrosis by suppressing the TGF-β1/Smad2 pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: